anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Noncommunicable diseases (NCDs) contribute significantly to global morbidity and mortality, with cancer being one of the leading causes. In this prospective observational study, we aimed to investigate the prevalence and impact of endocrine disorders, specifically diabetes and thyroid dysfunction, in patients with advanced metastatic cancer undergoing cancer-directed therapy.
METHODS: Over 15 months, we recruited 100 histologically proven advanced metastatic cancer patients from the Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishikesh, and conducted institutional-based prospective observational study. All participants over 18 years of age, treatment-naive, and potential candidates for systemic chemotherapy with an expected clinical survival of at least 6 months were included in the study. Patients with prior therapy, secondary neoplasms, and those unable to complete 3 months of palliative chemotherapy were excluded. Patients were assessed for diabetes and thyroid function at presentation, after 3 and 6 months of cancer-directed standard therapy. These data were analyzed, processed, and presented as results.
RESULTS: The mean age of participants was 50.45 years, with a near-equal distribution of males and females. At baseline, 10% of the study population had preexisting endocrine disorders (2% hypothyroidism, 8% diabetes). By the end of 6 months, the prevalence increased to 18%, with females being more affected. Notably, the prevalence of new-onset endocrine disorders during cancer-directed therapy was only 3% for diabetes and 4% for thyroid dysfunction.
CONCLUSION: Analysis of sociodemographic and cancer-related characteristics showed no significant association with changes in diabetic and thyroid status at 3 and 6 months. However, substance use, particularly smoking, was associated with an increased risk of diabetes development (p < .05). Cancer type and treatment regimen did not show statistically significant correlations with endocrine dysfunction.
IMPLICATIONS: Our study highlights the importance of considering endocrine disorders in advanced metastatic cancer patients undergoing therapy. The prevalence of diabetes and thyroid dysfunction increased during cancer-directed therapy, particularly in females. Careful monitoring and timely intervention are essential to improve the quality of life for these patients. Further research is warranted to explore the long-term effects of cancer-directed therapy on endocrine health and develop tailored management strategies for this vulnerable population.
This novel study applies targeted functional proteomics to examine tissues and cells obtained from a cohort of individuals with severe obesity who underwent bariatric surgery (BS), using a Reverse-Phase Protein Array (RPPA). In obese individuals, visceral adipose tissue (VAT), but not subcutaneous adipose tissue (SAT), shows activation of DNA damage response (DDR) markers including ATM, ATR, histone H2AX, KAP1, Chk1, and Chk2, alongside senescence markers p16 and p21. Additionally, stress-responsive metabolic markers, such as survivin, mTOR, and PFKFB3, are specifically elevated in VAT, suggesting both cellular stress and metabolic dysregulation. Conversely, peripheral blood mononuclear cells (PBMCs), while exhibiting elevated mTOR and JNK levels, did not present significant changes in DDR or senescence markers. Following BS, unexpected increases in phosphorylated ATM, ATR, and KAP1 levels, but not in Chk1 and Chk2 nor in senescence markers, were observed. This was accompanied by heightened levels of survivin and mTOR, along with improvement in markers of mitochondrial quality and health. This suggests that, following BS, pro-survival pathways involved in cellular adaptation to various stressors and metabolic alterations are activated in circulating PBMCs. Moreover, our findings demonstrate that the DDR has a dual nature. In the case of VAT from individuals with obesity, chronic DDR proves to be harmful, as it is associated with senescence and chronic inflammation. Conversely, after BS, the activation of DDR proteins in PBMCs is associated with a beneficial survival response. This response is characterized by metabolic redesign and improved mitochondrial biogenesis and functionality. This study reveals physiological changes associated with obesity and BS that may aid theragnostic approaches.
The present invention relates to novel fetal tissue related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as 'fetal tissue antigens', and the use of such fetal tissue antigens for detecting disorders of the fetal tissues, particularly the presence of cancer and cancer metastases. More specifically, isolated fetal tissue associated nucleic acid molecules are provided encoding novel fetal tissue associated polypeptides. Novel fetal tissue polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human fetal tissue associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to fetal tissue and/or proliferating cells, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypetides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
IMPORTANCE AND OBJECTIVE: Menopause is a reproductive transition affecting half the world's population. Stigma and limited availability of evidence-based treatments that support biopsychosocial well-being mean that this life stage is often associated with challenging symptoms and reduced quality of life (QoL). The aim of this review was to examine the extent literature on psychological and mind-body interventions to manage perimenopausal and postmenopausal symptoms, and apply an interdisciplinary clinical, research, and cultural knowledge framework to guide recommendations for improving QoL and healthy aging in this population. We also aimed to understand the ideal delivery mode for such interventions.
METHODS: Using Scopus, Medline, and PubMed, a review of systematic reviews, guidelines, and randomized controlled trials was undertaken to examine the use of psychological and mind-body interventions to improve menopause-related QoL and symptoms, including hot flushes, depression, anxiety, fatigue, pain, and sleep; conclusions were based on an analysis of this available evidence and linked to clinical and cultural considerations.
DISCUSSION AND CONCLUSION: Empirical support exists for a number of psychological and mind-body approaches to support QoL and symptoms during the menopause transition. The literature also identifies the need for menopause care that is culturally responsive.An online multimodal model of menopause care is thus recommended, incorporating evidence-based treatments (eg, cognitive behavioral therapy, yoga, hypnosis) and treatment techniques (eg, mindfulness, and education including nutrition support), as well as First Nations wisdom. We also recommend financial well-being approaches to support people undergoing menopause. Integrated, multimodal approaches should be available online to remove time, location, and healthcare access barriers, and be designed with diverse consumers to ensure equity for those underserved due to region, LGBTIQ+ assigned female at birth status, and for multicultural and First Nations people.
PURPOSE: The clinical efficacy and safety of ertapenem use in patients undergoing renal replacement therapies (RRT) are not well-documented. Therefore, we aimed to investigate the safety and efficacy of ertapenem in patients with sepsis secondary to Enterobacterales who are undergoing RRT.
METHODS: A retrospective cohort study was conducted on patients who met the inclusion criteria at our hospital between May 2015 and December 2021. The primary endpoint was 30-day mortality. Secondary endpoints included clinical cure, microbiologic cure, recurrence rate, and incidence of seizures.
RESULTS: During the study period, 158 patients met the inclusion criteria. Of these, 86 were male (54.4%), the mean age was 66.4 ± 13.8 years, and the mean weight was 77 ± 22.4 kg. The most common diagnosis was bacteremia in 48 (30.4%) subjects, followed by urinary tract infection in 39 (24.7%) subjects, and pneumonia in 35 (22.2%) patients. The most isolated pathogens were Escherichia coli, followed by Klebsiella species. The median ertapenem dose was 0.5 g intravenously (IV) daily in those who received intermittent hemodialysis (IHD) and 1 g IV daily for those who received continuous veno-venous hemofiltration (CVVH). The 30-day mortality rate was 24%, the clinical cure rate was 89.2%, the microbiologic cure rate was 82%, the 30-day recurrence rate was 41.1%, and the incidence of seizures was 2.5%. Multivariate logistic regression analysis indicated that age (OR 1.04 [95% CI: 1.003-1.075]), being critically ill at therapy initiation (OR 2.9 [95% CI: 1.1-7.5]), and Enterobacterales other than Klebsiella species and Escherichia coli (OR 3.8 [95% CI: 1.1-12.5]) were significant independent risk factors associated with mortality in this population. Ertapenem dose was not associated with mortality.
CONCLUSION: Our findings suggest that the commonly used doses of ertapenem in patients undergoing IHD and CVVH are clinically effective but may pose a higher risk of seizures. A comprehensive pharmacokinetic study is needed to determine the most effective and safe dose for this population.
The function of natural killer (NK) cells is regulated by inhibitory and activating signals delivered by cell surface receptors, 1-7F9 is a fully human monoclonal antibody (mAb) directed against KIR2DL1 and K1R2DL2/3 receptors that blocks its interaction with its HLA-C ligands breaking NK cell tolerance to autologous tumor ceils. Lεnalidomide has been shown to increase NK cell cytotoxicity in vitro. The combination of lenalidomide and 1-7F9 enhanced NK cell mediated cytotoxicity against U266 cells beyond that observed with each agent alone. Lenalidomide also increased the expression of NKG2D, DNAM-I and TRAIL ligands including: MICA, ULB P2, CD1 12 and DR 4 on U266 cells. In in vitro cytotoxicity assays, lenalidomide enhanced the susceptibility of myeloma cell lines to NK ceil. The NK ceil signaling pathways was also explored after lenalidomide treatment and the results show that lenalidomide may upreguiate the phospho-SHIP1 (Tyr1020) and has no effect on phospho-p44/42 (ERK 1/2) (Thr202/Tyr204) in NK cells. These results provide pre  clinical rationale for clinical investigation of 1-7F9 anti-KIR mAb and lenalidomide in MM.
PURPOSE: A composition containing Lysimachiae Foenumgraeci Herba ethanol extract is provided to prevent and treat lung cancer. CONSTITUTION: A composition for preventing and treating lung cancer contains Lysimachiae Foenumgraeci Herba ethanol extract as an active ingredient. The composition contains pharmaceutically acceptable carrier or diluents. The lung cancer is non-small cell lung cancer. The non-small cell lung cancer is caused by adenocarcinoma, squamous cell carcinoma, or large cell carcinoma. A cosmetic composition for preventing lung cancer contains the ethanol extract containing cosmetologically acceptable cosmetic product additive. [Reference numerals] (AA) Lysimachiae Foenumgraeci Herba
<P>PROBLEM TO BE SOLVED: To provide a gene exasperating the production of amyloid-β protein, to provide the protein, and to provide their uses.  <P>SOLUTION: The gene exasperating the production of the amyloid-β protein. The protein or its salt encoded in the gene. An antibody against the protein. A diagnostic agent or medicine containing the antibody. A method for screening a compound effective for treating Alzheimer's disease with the protein or the like. A kit used for screening the compound effective for treating Alzheimer's disease, and containing the protein or the like.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
This group will use the Identifor tool and Companion app for a period of 6 months. They will also receive standard referral to employment agencies.
For this pilot study patients who meet the conventional criteria for pulmonary rehabilitation at their clinical appointments will be recruited and scheduled to return for the study. After completing the informed consent, patients will be taught how to don and doff the pulse oximeter, the source of the heart rate and oxygen signals. Patients will participate in a demonstration on how to perform the intervention. Recruitment will continue until five patients have completed the pilot in a clinic setting. If necessary, the prototype will be modified and testing resumed. Once the prototype system has met the criteria for success in the clinic, five of patients will be asked to use the prototype at the clinic and to take it home for a week and perform the intervention at least five times.
FIELD: organic chemistry of heterocyclic compounds, biochemistry, pharmacy. SUBSTANCE: invention relates to arylalkanoylpyridazines of the formula (I)   where B means A, OA, NH 2 , CF 3 , aromatic heterocycle taken among pyridine, pyrazine and pyrimidine; Q is absent or means alkylene with 1-6 carbon atoms; R 1  and R 2  mean independently each of other OR 5  where R 5  means A or cycloalkyl with 3-7 carbon atoms; A means alkyl with 1-10 carbon atoms, and to their physiologically acceptable salts. Compounds of the formula (I) and their physiologically acceptable salts are inhibitors of phosphodiesterase IV and can be used for preparing the medicinal agent with indicated action being for treatment of asthmatic diseases preferably. Except for, invention relates also to method of synthesis of compounds of the formula (I), method of preparing pharmaceutical compositions useful for inhibition of activity of phosphodiesterase IV and to pharmaceutical composition. EFFECT: improved method of synthesis and preparing, valuable medicinal and biochemical properties of compounds. 8 cl, 25 ex
Childhood cancers cover a wide range of diseases; leukemia, central nervous system cancers and lymphomas are the most common ones among them. Acute lymphoblastic lymphoma (ALL) is the most common childhood cancer and 78% of leukemia's reported to be ALL. During medical treatment children with leukemia are at risk of neuromuscular and musculoskeletal complications such as reduced ankle range of motion, reduced muscle strength, gross and fine motor performance impairment, decreased energy consumption, osteonecrosis and osteoporosis. These conditions can develop as a result of cancer or its treatment. These neuromuscular and musculoskeletal complications can affect dynamic balance, endurance and quality of life of the children. Childhood cancers have negative effects on sleep; sleep complaints can develop with the diagnosis and continue even after recovery period.The aim of this study is to identify the status of sleep, fatigue, and quality of life in children with various types of cancer and to examine the relationship between these conditions. In addition, families will be assessed about their children's conditions and satisfaction with the health care they receive.The general situation of children will be determined according to findings from this study.
Anthracycline chemotherapeutics like doxorubicin (DOX) are widely used against various cancers but are accompanied by severe cardiotoxic effects that can lead to heart failure. Through whole transcriptome sequencing and pathological tissue analysis in a murine model, our study has revealed that DOX impairs collagen expression in the early phase, causing extracellular matrix anomalies that weaken the mechanical integrity of the heart. This results in ventricular wall thinning and dilation, exacerbating cardiac dysfunction. In this work, we have identified 5-hydroxytryptophan (5-HTP) as a potent inhibitor of gap junction communication. This inhibition is key to limiting the spread of DOX-induced cardiotoxicity. Treatment with 5-HTP effectively countered the adverse effects of DOX on the heart, preserving ventricular structure and ejection fraction. Moreover, 5-HTP enhanced mitochondrial respiratory function, as shown by the O2k mitochondrial function assay, by improving mitochondrial complex activity and ATP production. Importantly, the cardioprotective benefits of 5-HTP did not interfere with DOX's ability to combat cancer. These findings shed light on the cardiotoxic mechanisms of DOX and suggest that 5-HTP could be a viable strategy to prevent heart damage during chemotherapy, offering a foundation for future clinical development. This research opens the door for 5-HTP to be considered a dual-purpose agent that can protect the heart without compromising the oncological efficacy of anthracycline chemotherapy.
PURPOSE: To enjoy favorable refreshingness in summer season and have skin firmness effect owing to low temperatures, by using a makeup cosmetic prepared by formulating specific powder, lubricant and water in specified proportions after its chilling in e.g. a refrigerator. CONSTITUTION: A makeup cosmetic composed of 93-10wt.% of water-repelling- treated powder, 2-40wt.% of a lubricant and 5-50wt.% of water is chilled to a temperature >=0 deg.C lower than room temperature. The powder is e.g. titanium dioxide, zinc oxide. The water-repelling treatment is carried out by using e.g. a fluorine compound. The lubricant is e.g. stearyl alcohol, glycerol, isostearic acid, vaseline.
This is a Platform Protocol that allows evaluation of more than one treatment in a single trial structure, to be run within EPPIC-Net. Instead of testing individual assets in a series of clinical trials, this Platform Protocol sets out the framework for testing multiple assets related to PDPN. This provides an efficient approach to evaluate multiple therapies under a single infrastructure in a timely fashion. The Platform Protocol also allows efficiencies by creating the possibility of sharing information across assets, such as data from control conditions.

This Platform Protocol is for a platform design to allow for the testing of multiple assets. Some platform trials allow direct comparisons of competing therapies for the same condition. However, for this EPPIC-Net platform trial, there will not be direct comparisons of assets to one another. Instead, assets will only be compared to a placebo. This is in service to the EPPIC-Net primary goal of accelerating the development of pain treatment because, based on feedback from asset-holders, the possibility of comparison of assets to one another or to an active drug would be a deterrent for asset-holders' participation in EPPIC-Net.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to preparation of an agent taken after solid dosage forms and to a method for taking solid dosage forms. The agent taken after solid dosage forms characterised by viscosity within 25 to 3000 centipoises at temperature 20 degrees Celsius contains polysaccharide consistence promoting substances in amount 0.05 to 0.08 weight fractions, and water. The method for taking solid dosage forms consists in separate intake of the agent with the solid dosage form taken in the second or following intake with said agent. ^ EFFECT: said agent and method provide higher safety of oral administration of solid dosage forms. ^ 2 cl, 3 ex
This is an open-label, single center study to investigate the effect on human intestinal microflora of multiple doses of ceftobiprole treatment administered at 8 hours intervals for 7 consecutive days. Careful investigation of the effect of Ceftobiprole treatment on the intestinal microflora is of importance since alteration of the intestinal microflora balance may facilitate colonization by pathogenic bacteria strains or enable microorganisms already present in the normal microflora to develop resistance. A total of 7 fecal samples will be collected on day 2, 4, 7, 10, 14 and 21 for determination of ceftobiprole concentration in fecal, intestinal microflora pattern and measuring the susceptibility for Ceftobiprole of isolated bacterial strains. A total of 13 plasma samples will be collected on day 1, 4, 7, 10, 14 and 21 for determination of ceftobiprole concentration in plasma. Safety evaluations including physical examination, vital signs, clinical laboratory tests, electrocardiogram and adverse event monitoring will be performed throughout the study. 500 mg ceftobiprole, intravenous infusion over 120 minutes, every 8 hours for 7 consecutive days
The invention provides a composition capable of improving bone mineral density, which relates to a bone mineral density composition. The objective of the invention is to overcome the problems of great toxic and side effects, high cost, etc. of conventional medicines used for increasing bone mineral density. The composition capable of improving bone mineral density comprises, by mass, 40 to 180 parts of hydrolyzed yolk powder, 250 to 1050 parts of eucommia bark, 400 to 1800 parts of kudzu vine root and 150 to 750 parts of fortune's drynaria rhizome. The hydrolyzed yolk powder used in the invention is a functional substance extracted from egg yolk and is cheap, easily available and suitable for industrial production. The three compatible traditional Chinese medicines are materials applicable to health food or both edible and medicinal materials; the traditional Chinese medicines and new resource food are reasonably compounded and exert a synergistic effect, so the effect of improvement of bone mineral density is achieved. The composition has the advantages of simple and practicable preparation, controllable quality and suitability for industrial production. The composition provided by the invention is applicable to the field of health products.
The invention relates to an integrated novel form preparation technology for polyporus umbellatus decoction and a production method thereof. The effective effects of the polyporus umbellatus  decoction comprise the following raw materials in parts by weight: 30 parts of polyporus umbellatus, 30 parts of tuckahoe, 30 parts of oriental waterplantain rhizome, 30 parts of donkey-hide gelatin and 30 parts of talcum. The production process of the polyporus umbellatus decoction comprises the steps of supersonic airflow pulverizing, alcohol water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spraying and drying, nanometer grinding, uniform high-pressure emulsification, nano particle preparation and the like. According to the invention, the multi-synergism, multi-target and other advantages embodied by a nano-carrier coupling technique are attached to apply. After the polyporus umbellatus decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The polyporus umbellatus decoction can be taken by internally and externally feeding and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of human body. In addition, the polyporus umbellatus decoction can be prepared into films and transdermal agents which are respectively attached to different parts of human body according to the midnight-noon ebb-flow and qi and blood flowing rule of human body and can be directly absorbed through skin.